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Malignant glioma is the most common brain tumor in adults and is associated with a very poor prognosis. Mutations in the
p53 tumor suppressor gene are frequently detected in gliomas. p53 is well-known for its ability to induce cell cycle arrest,
apoptosis, senescence, or diﬀerentiation following cellular stress. That the guardian of the genome also controls stem cell self-
renewal and suppresses pluripotency adds a novel level of complexity to p53. Exactly howp53 works in order to prevent malignant
transformation of cells in the central nervous system remains unclear, and despite being one of the most studied proteins, there
is a need to acquire further knowledge about p53 in neural stem cells. Importantly, the characterization of glioma cells with
stem-like properties, also known as brain tumor stem cells, has opened up for the development of novel targeted therapies. Here,
we give an overview of what is currently known about p53 in brain tumors and neural stem cells. Speciﬁcally, we review the
literature regarding transformation of adult neural stem cells and, we discuss how the loss of p53 and deregulation of growth
factorsignalingpathways,such asincreased PDGF signaling,lead to brain tumordevelopment.Reactivation ofp53 in braintumor
stem cell populations in combination with current treatments for glioma should be further explored and may become a viable
future therapeutic approach.
1.Introduction
The most frequent form of brain tumor in adults is
glioma [1]. Gliomas are classiﬁed as astrocytomas, oligo-
dendrogliomas, oligoastrocytomas, and ependymomas [2].
Astrocytoma is the most common subclass of glioma and
is graded on a WHO scale of I to IV, whereas oligo-
dendrogliomas and oligoastrocytomas are usually classiﬁed
as grade II or grade III [3]. Grade IV astrocytic tumor,
commonlyknownasglioblastoma(GB),isthedeadliestform
ofbrain tumorthat despitemultimodal therapy onlyshows a
median survival of 12–15 months [4]. Recent transcriptome
and genome proﬁling of brain tumors in combination with
advances in stem cell biology has led to an improved
understanding ofthemolecularpathologyofthisdisease and
revealed novel targets for therapy [5].
The p53 tumor suppressor gene is frequently mutated
or deleted in human tumors and is often found mutated
or lost early in glioma formation [6, 7]. p53 can trigger
diverse cellular programs such as cell cycle arrest, apoptosis,
diﬀerentiation, DNA repair, autophagy, and senescence [8].
One prevailing hypothesis is that GB could arise and
recur because of malignant transformation of neural stem
cells residing in protected niche areas [9]. Recently, novel
functions of p53 in stem cells have been characterized
including suppression of pluripotency and inhibition of
stem cell self-renewal [10]. Despite being one of the most
extensively studied proteins, there is still a need to acquire
further knowledge and insight into p53 function in stem
cells including neural stem cells. What function of p53 is the
most important one to inactivate for brain tumor initiation
and progression? Could it be the ability of p53 to restrain
self-renewal and to promote diﬀerentiation, or is it the pro-
apoptotic and cell cycle regulating activity? Here we discuss
the role of p53 in gliomagenesis and the signiﬁcance of p53
in relation to brain tumorstem cells. We review the literature
regarding the neoplastic potential of neural stem cells, and
we describe how the loss of p53 in parallel with deregulation2 Journal of Oncology
of growth factor signaling pathways promotes brain tumor
development. Finally, we discuss how the reactivation of
p53 in brain tumor stem cell populations could become
one viable approach to suppress proliferation and induce
diﬀerentiation and apoptosis of these cells.
2.GliomaGeneticsandGlioma Cellof Origin
2.1. p53 Pathway Inactivation in Glioma. Gliomas often
display mutations in the ARF-MDM2-p53 and p16INK4a-
CDK4-RB tumor suppressor pathways resulting in increased
genomic instability, loss of G1 cell cycle checkpoint control,
and evasion of apoptosis [2, 11]. Deregulation of the
PI3K/AKT/mTOR signaling pathway and hyperactivation
of receptor-tyrosine kinases (e.g., PDGFRα and EGFR) are
frequently observed in gliomas [2, 11]. GBs can be classiﬁed
as primary or secondary but are morphologically similar
[1] .Ap r i m a r yG Ba r i s e sw i t hn os i g n so fp r e v i o u sl o w e r -
grade tumor and often displays loss of the INK4A/ARF
tumor suppressor gene locus, PTEN mutation, and EGFR
ampliﬁcation and/or mutation [1]. Secondary GBs show a
previous history of progression from a lower-grade tumor
and TP53 mutations are frequent [2]. Recently, transcrip-
tome and genome proﬁling of GBs has revealed additional
genetic diﬀerences, and new subclasses of GB have been
deﬁned [12–14].
TP53 mutations occur early in glioma progression, and
grade II astrocytomas commonly display TP53 mutations
or loss of heterozygosity on chromosome 17p where TP53
resides [15, 16]. TP53 mutations are infrequent in medul-
loblastomas, pilocytic grade I astrocytomas, and ependymo-
mas [7]. The p53 tumor suppressor restricts cell growth and
proliferation following stress and is known as the guardian
of the genome [17]. p53 has pleiotropic anticancer functions
and plays a role in senescence, apoptosis, diﬀerentiation,
autophagy,metabolism, and angiogenesis [18].Thesediverse
cellular eﬀects can be attributed to the regulation of hun-
dredsofdiﬀerentgenesdirectlybyp53[8,19].Thetranscrip-
tional function of p53 is stimulated through increased levels
of the protein coupled to conformational changes triggered
by diﬀerent posttranslational modiﬁcations or p53- binding
proteins [20]. While approximately half of all human tumors
containamutationordeletionofTP53,therestofthetumors
often have inactivation of p53 through other mechanisms
including viral infection, loss of ARF, or overexpression of
MDM2 [21]. The MDM4 and MDM2 proteins suppress
p53’s transcriptional activity and target p53 for proteasomal
degradation, respectively [22]. It is therefore not a surprise
to learn that MDM2 gene ampliﬁcations are present in 10%
of primary GBs and that ampliﬁcations of MDM4 are found
in about 4% of GBs [23, 24]. Gliomas are also seen in
the Li-Fraumeni syndrome, a familial cancer predisposing
syndrome characterized by germ line TP53 mutations [25,
26]. It has been a widely held notion that somatic TP53
mutations are common in low-grade gliomas and secondary
GBs but more uncommon in primary GB. However recent
studies, which also included additional sequencing of TP53,
revealed that mutations are prevalent in primary GBs as well
[13, 27]. Another common and critical tumor suppressor
gene alteration in GB is loss of function of PTEN that occurs
in both primary and secondary GB [28].
Accumulatedexperimental and clinicalevidencesuggests
that the loss of p53 function is a key initial event in
glioma development in combination with other genetic and
epigenetic alterations [6, 7, 26, 29–34]. Numerous studies
havealso beencarriedoutinordertoinvestigatetheeﬀectsof
p53 overexpression in glioma cells. Evidently, p53 can block
cell cycle progression and induce morphological changes
resembling diﬀerentiation in glioma cell lines[35–37]. Given
these ﬁndings, therapeutic targeting of the p53 pathway still
seems highly interesting in glioma.
2.2. Neural Stem Cells. Tissue stem cells are considered to
be rare cells within organs with the ability to self-renew
and to give rise to all types of cells within the said organ
[38]. Examples of tissue stem cells include hematopoietic
stem cells, neural stem cells, and mammary gland stem cells
[38]. Embryonic stem cells on the other hand are isolated
from the inner cell mass of blastocysts, are pluripotent,
and can give rise to all cell types of the body [39]. Neural
stem cells are the self-renewing cells that generate the main
cells of the central nervous system (astrocytes, neurons, and
oligodendrocytes) [40]. New neurons are thought to be born
throughout adulthood in predominantly two regions of the
mouse brain [41]. These are the subventricular zone of the
lateral ventricle wall, from where new neuronal progenitor
cells migrate to the olfactory bulb via the rostral migratory
stream [42, 43], and the subgranular zone of hippocampus
[44]. Reynolds and Weiss were the ﬁrst to isolate neural
progenitor and stem cells from adult mouse brain [45].
Within the subventricular zone, cells can be classiﬁed as
type B neural stem cells and type C transit-amplifying cells
that give rise to neuroblasts (type A) [46]. Neural stem
cells are often studied in vitro using a method referred to
as the neurosphere assay developed by Reynolds and Weiss
[45], see also [47] for an update. Neural stem cells have the
properties of self-renewal, clonogenic capacity, and ability
to engraft, migrate, and give rise to diﬀerentiated progeny
[41, 46, 48].
2.3. Glioma Cell of Origin and the Cancer Stem Cell Hypoth-
esis. Several common tumor forms, including brain tumors,
have been shown to harbor a fraction of cells with stem-
like features referred to as cancer stem cells [49]. The
cancer stem cells are considered to be a relatively small
population of cells that are capable of self-renewal, and the
progeny of which canundergo diﬀerentiation to generate the
phenotypic heterogeneity observed in solid tumors [50, 51].
Cancer stem cell populations have been found in many
malignancies including those from breast [52], brain [53],
pancreas [54], colon [55], and the hematopoietic system
(acute myelogenic leukemia) [56]. Cancer stem cells show
malicious behavior including prolonged exit from the cell
cycle (quiescence), resistance to chemotherapeutic agents,
eﬃcient DNA repair, and resistance to apoptosis [57–60].Journal of Oncology 3
Using the approach of Reynolds and Weiss [45], several
groups reported on the growth of adult and pediatric glioma
cells cultured and propagated in the form of neurospheres,
also known in thiscontextas “gliospheres”[61–65]. The cells
capable of self-renewal and of forming new gliospheres and
with the ability to initiate the formation of a new tumor
in nude mice are known as the brain tumor stem cells.
These cells can also be referred to as brain tumor initiating
cells or glioma stem cells. It was shown that gliospheres
have an increased growth potential and features of aberrant
diﬀerentiation when directly compared to normal neuro-
spheres from the adult brain [66]. Cell sorting is based on
expression of the cell surface marker CD133 selected for
gliomacellswithstem-likefeatures[53],andCD133-positive
brain tumor cells are relatively resistant to radiation when
compared to CD133-negative cells [57]. The clinical value
of CD133-expression in tumors remains unclear, but some
groupshavereported that theincreased expression of CD133
is associated with a poor prognosis [67, 68]. However, recent
studies indicate that also CD133-negative brain tumor cells
can initiate tumor development and act as brain tumor stem
cells [69].
It is at present discussed whether cancer stem cells
represent a minority of the tumor cells [70]. If most cells
within the tumor are endowed with stem cell properties,
why should we focus our energy on targeting a speciﬁc sub-
population of cells? Debated is also whether cancer stem
cells originate from normal stem cells or from diﬀerentiated
cells that have acquired the ability to self-renew [50], and
this discussion is especially dynamic within the brain tumor
research community [5, 71, 72]. It still remains unclear
if gliomas (in general) originate from multipotent neural
stem or progenitor cells, restricted neural progenitors, or
mature glia cells that have undergone the process of de-
diﬀerentiation [71].
3.Novel Functionsofp53 inNeuralStemCells
A number of recent studies show that p53 has a critical
function in neural [73], mammary [74], hematopoietic [75,
76] and embryonic stem cells [77] by regulating self-renewal,
symmetric division, quiescence, survival, and proliferation.
Two main functions of p53 can be distinguished in relation
to stem cell behavior. These can be described as the
abilities of p53 to induce diﬀerentiation and to suppress de-
diﬀerentiation and evidence in the literature supports a role
for p53 in both of these processes [10, 78–81].
In the mouse brain, p53 is critical for induction of
apoptosis in neural progenitors and postmitotic neurons
duringdevelopmentofthecentralnervoussystem[33],anda
subset of Trp53 knockoutmice developexencephaly [82, 83].
Furthermore, neuronal cells are sensitive to p53-dependent
apoptosis following irradiation, exposure to chemothera-
peutic agents, and ischemia [84]. p53 regulates cell cycle
progression and apoptosis but it can also directly modulate
the transcription of genes that are speciﬁcally required for
neuronaldiﬀerentiation[81,84].Theroleofp53inapoptosis
of neuronal cells is relatively well understood [85, 86], but
less is known about p53 function in astrocytes, oligoden-
drocytes and their precursors. Oligodendrocyte precursors
cultured in vitro can undergo p53-dependent diﬀerentiation
although the cells appear to have a low basal level of p53
expression [87]. Both astrocytes and oligodendrocytes can
undergo apoptosis following infection with an adenovirus
expressing p53 [88]. Although speculative, cells of the
glial lineage may be more prone towards p53-induced
diﬀerentiationand senescence following stress than neuronal
cells.
What is the function of p53 in the neural stem cells? The
enhanced proliferative capacity of neural precursors from
Trp53 knockout mice was described in the early 90s [89].
Later, it was found that p53 is expressed at higher levels
in cells in the neural stem cell niche than in other regions
of the adult mouse brain [73]. Cells in the brain’s lateral
ventricle stem cell niche displayed an increased proliferation
rate in Trp53 knockout mice compared to wild-type [73].
It was also found that a p53 deﬁciency in neurospheres
resulted in increased self-renewal capacity, increased cell
proliferation and a reduction in apoptosis [73]. Analysis
of the stem cell transcriptome from wild type and Tp53
knockout mice identiﬁed several genes that were down-
regulated in p53-null neurospheres, importantly p21 and
p27, established negative regulators of cell proliferation [73].
In a related study, Gil-Perotin et al., found a p53-dependent
eﬀect on diﬀerentiationthe and they could determine that
loss of p53 increased the number of Tuj1+ neuroblasts in
the subventricular zone in vivo [31]. Regions with mild
to moderate hyperplasia, resembling “microtumors” were
also apparent in some Trp53 knockout mice [31]. The
increase in cell number was apparently not due to loss
of apoptosis, as it could be compensated for, and it was
argued that this is the reason for why there are no tumors
in Trp53 knockout mice [31]. Also by using olfactory bulb
neural stem and progenitor cells cultured as neurospheres
it was found, in agreement with the previous studies, that
loss of p53 can promote neurosphere formation and stem
cell self-renewal [90]. Furthermore, loss of p53 facilitated
diﬀerentiationofprogenitorcellsinto Tuj1-positive neurons,
withacorrespondingmoderatedecreaseinmatureastrocytes
[90]. In summary, a number of studies show that the loss of
p53 provides an advantage to neural stem cells and/or early
progenitor cells [31, 73, 90]. However, the loss of p53 alone
does not cause brain tumors within the relatively short life
span of Trp53 knockout mice [91].
p53-mediatedcontrolofstemcellfunctionshasalsobeen
studiedinothertissues.Forexample,p53hasacriticalrolein
regulating hematopoieticstem cell quiescence[75, 76]. Tran-
scriptome analysis identiﬁed Gﬁ-1 and Necdin as p53 target
genes involved in regulating quiescence [76]. In mammary
glandstemcells,p53controlspolarityofmammary epithelial
stem cell divisions [74]. In bone formation, the loss of p53
not only accelerates early osteogenesis from mesenchymal
stem cells but actually prevents terminal diﬀerentiation to
a mature osteocytic phenotype [92]. These studies taken
togetherfurtherstrengthenthenotionthatp53controlsstem
cell self-renewal and diﬀerentiation, but that it may not only
do so in a cell-type-speciﬁc manner.4 Journal of Oncology
4.BrainTumorStemCellsand p53
4.1. Inactivation of p53 in Neural Stem Cells. Perhaps the
suppression of incipient cancer stem cells is one activity
by which p53 can inhibit tumor growth [8], but what are
the mechanistic links between p53 and the emergence of
cancer stem cells, if any? p53 was found to repress the
cancer stem cell marker gene CD44 in an experimental
breast tumor model [93]. Overexpression of CD44 on the
other hand blocked p53-dependent apoptosis, leading to
expansion of tumor-initiating cells [93]. It would be of
interest to determine if similar mechanisms are involved
also in brain tumor development, but exactly how the loss
of p53 function leads to transformation of normal cells in
the central nervous system remains unclear. Development
of a brain tumor may begin with a mutation in the p53
gene which makes neural stem cells proliferate faster and
perhaps also migrate out of the niche like their specialized
progenies [9]. Wang and coworkers carried out a series
of experiments using mice engineered to have an internal
deletion mutation in Tp53, Δ exon 5-6, speciﬁcally in neural
stem and progenitorcells [94]. They found that a majority of
mice developed malignant brain tumors and that the same
mutantp53wasdetectedinthetumorcellsbutnotinnormal
cells. Mutant p53 protein was detectable in a minority of
proliferative neural stem cells two months after birth. It
was argued that it is presumably the mutant-p53-expressing
cell population with features of transit-amplifying cells that
drives tumor initiation [94]. The hypothesis that stem cells
residing in the subventricular zone can give rise to gliomas is
also supported by otherstudies [9, 29, 95, 96]. An interesting
point of view is that tissue stem cells remain undiﬀerentiated
due to environmental cues in their particular niche, and the
stem cells diﬀerentiate when they leave that niche, or no
longer receive proper signals from the niche [97].
GB was initially considered to be a monoclonal tumor
and the patternsofclonalexpansion ofcellswith mutantp53
supportedthisnotion[34]. However,given the heterogeneity
of GB taken together with the recent ﬁndings that there
are coexisting populations of cells with diﬀerent p53 status
within the same tumor, we must also consider polyclonal
events [98]. GB is composed of several types of cells,
and some phenotypes or clones may be better suited for
the speciﬁc environment but they could still coexist with
other sub-optimal lines of tumor cells [71]. One of these
sub-optimal lines could however following a novel and
diﬀerent type of stress adapt and instead become the most
successful line, and this type of event could contribute to
treatment resistance of GB [5, 71]. Phenotypically diﬀerent
subpopulationsofcellsmayevenbeneﬁtfromeach otherand
thus remain coexisting in the tumor [99]. As with regard to
p53, perhaps the majority of tumor cells beneﬁt from having
mutant p53 or no p53 at all, but may some tumor cells thrive
when carrying wild-type p53?
4.2. Stem Cell Signatures in Brain Tumor Cells. Pluripotent
stem cells can be generated from normal ﬁbroblast cultures,
and in principle four key pluripotency genes essential for the
production of pluripotent stem cells were deﬁned, namely:
Oct-3/4, Sox2, c-Myc, and Klf4 [100]. Of interest is also the
recently established function ofthe p53 pathway insuppress-
ing reprogramming of normal cells to induced pluripotent
stem cells (iPSCs) [101–104]. Silencing of p19ARF, an
upstream regulator of p53, facilitates reprogramming as well
[105]. It remains unclear how p53 blocks reprogramming
of cells to iPSCs, but one possibility is that it could be
related to the higher sensitivity of iPSCs to stress than
the more diﬀerentiated cells from which they were initially
derived [80]. The process of creating iPSCs resembles the
creation of tumor cells by speciﬁc factors and highlights
the similarity between iPSCs and cancer stem cells [79].
GBs frequently overexpress genes typical of neural stem
cells including Sox2 [106], Myc [27]a n dO c t 4[ 107]. A
hallmark of some poorly diﬀerentiated tumors, including
GB, is a stem cell signature [108]. The malignant progression
of glioma may be associated with the emergence of such a
signature[109].Therefore,targetingpluripotency-associated
moleculessuch asMycandSox2,combinedwith reactivation
of p53, speciﬁcally in brain tumor stem cell populations
could become one approach to eﬀectively reduce tumor
growth. In fact, c-Myc is required for brain tumor stem
cell growth [110], and in normal neural stem cells, loss
of c-Myc on its own attenuates self-renewal and induces
diﬀerentiation towards the glial lineage [111].
Inthis context it should also be mentioned that p53 plays
a speciﬁc role in the DNA-damage response of embryonic
stem cell [77]. Embryonic stem cells lack a distinct G1/S cell
cycle checkpoint [112], but new evidence shows that p53 in
response to DNA damage acts to induce diﬀerentiation and
tosuppressexpressionofthepluripotencyfactorNanog[77].
Whether a similar mechanism is involved in the neural stem
cell stress response, remains of interest to determine.
4.3. Other Regulators of p53 in Brain Tumor Stem Cells.
We must also take into account the function and expres-
sion of proteins and microRNAs that regulate p53. Olig2
is a central-nervous-system-restricted transcription factor
highly expressed in brain tumor stem cells and required
for neural progenitor cell proliferation [113]. Olig2 directly
suppresses p21, a downstream key target of p53, and Olig2
is therefore presumably an important antagonist of the p53
pathway during glioma development [113]. Interestingly,
loss of p21 increases the proliferative capacity of neural
stem cells [114]. Another important regulator of p53 is
Gli1, a downstream mediator of Hedgehog signaling. Gli1
can repress p53 activity and Gli1 promotes an increase
in neural stem and progenitor cell pools [115]. However,
p53 in turn can suppress Gli1 function and proper Gli1
subcellular localization [116]. Interestingly, Gli1 function
also depends on Nanog [116]. These studies revealed novel
intricate signaling networks in stem cells and how they are
connected to p53 [117]. Recently, Bcl2L12 (Bcl2-like 12) a
protein found overexpressed in GB that prevents apoptosis,
was shown to interact with and inhibit p53 [118]. As
mentioned, loss of the tumor suppressor PTEN is a frequent
event in brain tumors [28]. Interestingly, PTEN is critical
in restricting neural stem cell self-renewal and proliferationJournal of Oncology 5
similar to p53 [119, 120], and the combined loss of p53
and PTEN promotes a synergistic increase in neural stem
cell self-renewal associated with elevated levels of c-Myc and
rapid growth of gliomas in vivo [27, 121]. In turn, c-Myc
promotes an even more malignant phenotype of the tumor
[27]. Finally, regulation of the p53 pathway by microRNAs is
likely to be of importance also in brain tumor development
and brain tumor stem cells [122].
5.Interplaybetweenp53and Overactive
PDGFSignaling
A number of recent studies using animal models have
provided compelling evidence that gliomas can be induced
from neural stem cells, provided combinations of several
diﬀerent tumor suppressors are deleted (e.g., Pten, Nf1 and
Trp53) [29, 94–96]. Loss of p53 in neural stem cells has
in mouse models been proven as an important step in
the initiation of gliomas [123]. Using a diﬀerent approach,
others have shown that persistent mitogen signaling (e.g.,
PDGF-B) can promote gliomagenesis also in lineage-
restricted progenitor cells giving rise to oligodendroglioma-
like tumors [124]. Therefore, development of gliomas may
take divergent pathways and start in diﬀerent cell types
and locations [5]. Oligodendrocyte progenitor cells express
PDGFRα and can be induced to proliferate when stimulated
with PDGF [125]. The use of retrovirus or adenovirus
vectorsto introduce PDGF-Binnewbornmice brainsmostly
results in Gfap−/Ng2+/Olig2+tumorsthatbytranscriptome
analysis are similar to oligodendrogliomas [126–128]. This
is true even if the virus is directed to neural precursors
by the Nestin-tva or Gfap-tva systems [129, 130]. The
oligodendroglioma-likefeatureshavebeeninterpretedasdue
to PDGF’s ability to modulate the balance between neuronal
and glial cells generated from neural stem cells, in favor of
oligodendrocyte progenitors [127].
In a recent report, transgenic mice were generated
expressing PDGF-B in brain under control of the human
GFAP promoter [32]. These mice were shown to be similar
to wild type mice, but on a Tp53-null background they
developed large GB-like brain tumors at a high frequency, in
spiteofthefact thatTp53-null micedonototherwisedevelop
brain tumors [32, 91]. The tumors were very heterogenous,
displaying many diﬀerent cell lineage markers, including
stem cell markers. Early lesions displayed abundant Gfap-
positive cells, although the larger tumors partly lost the
expression ofGfap. TheGfap promoterismostactivearound
birth and remains active in both astrocytes and neural
stem cells of the adult brain; however; the mice developed
brain tumors only in adult life, at 2–6 months of age [32].
Therefore, distinct possibilities of glioma cells of origin need
to be considered including (1) adult neural stem cells that
lose their diﬀerentiation capacity and (2) mature astrocytes
that dediﬀerentiate due to the lack of p53. These PDGF-
induced experimental gliomas are similar to human GBs
in that the glial tumor cells express Pdgfrα whereas the
vasculature expresses Pdgfrβ in pericytes [131]. The model
was created to mimic human secondary GBs character-
ized by combined PDGFRA overexpression/ampliﬁcation
and TP53 deletion/mutation, and results did prove that
this combination is instrumental in generating GBs. A
previous report described a signiﬁcant association between
PDGFRA expression, as analyzed at the mRNA level by in
situ hybridization and LOH17p in human gliomas [132].
Recently, by the help of high-throughput genome and
transcriptome analyses, human secondary GBs were shown
to be similar to the proneural type of primary GBs and
associated with PDGFRA ampliﬁcation, TP53 and PTEN
deletion/mutation, IDH1 mutation and also disturbances in
the PI3K signaling pathway, and ﬁnally by the expression of
oligodendrocyte markers [133].
Loss of function of p53, together with overactive growth
factor signaling, contributes to glioma formation. In the
transgenic mice expressing PDGF-B in astrocytes, tumors
developed in homozygously deleted Trp53 but not in
heterozygous mice [32]. Furthermore, PDGF-B retrovirus-
induced brain tumors developed at a higher frequency and
with shorter latency when injections were performed in
Trp53-null than in wild type mice, and in a Trp53-null
background these tumors showed higher p-Akt and lower
Pten levels [134]. Still, the mechanism of the combined
PDGF-B/Trp53 null eﬀect has not yet been clearly deﬁned.
One guess is that the Trp53-null status directly or indirectly
allows for proliferation of Pdgfrα-positive precursors in
the brain and/or for upregulation of Pdgfra expression at
the promoter level. Cultured, otherwise normal Trp53-null
brain cells show an increased survival and proliferation in
vitro, coupled with upregulation and activation of Pdgf-
receptors [134]. Other mechanisms need to be considered as
well. PDGF signaling is known to expand the pool of glial
progenitors generated from neural stem cells [135]. Given
the fact that the lack of p53 may in addition result in an
undiﬀerentiatedstateofthesecells,anincreaseinthenumber
of glial precursors promoted by PDGF, possibly induced to
migrate [136], but unable to diﬀerentiate further, may be all
that it takes to create a lethal neoplasm in the mouse brain.
We needtoconsiderthat thehuman brainhas tightercontrol
mechanisms than the mouse brain, but The Cancer Genome
Atlas (TCGA) and other similar high-throughput screening
projects provide us with excellent tools to identify additional
molecules and mechanisms aﬀected in human brain tumors
[12].
6.TherapeuticOpportunities
Treatment of brain tumor patients is extremely challenging
because the normal brain is highly susceptible to damage
during therapy, the brain has a very limited capacity to
repair itself, and several drugs cannot cross the blood-
brainbarrier to act on tumors in the CNS [5]. Brain tumor
cells are also highly inﬁltrative and can hide in apparently
normal partsofthebrain[137].Paradoxically,nonmalignant
neuronal cells are highly vulnerable to stress and respond
with the induction of p53-dependent apoptosis [84], yet
glioma-derived cells show resistance to apoptosis-inducing6 Journal of Oncology
stimuli[138].StandardtreatmentforGBissurgery,radiation
therapy and concomitant and adjuvant treatment with the
chemotherapeutic agent temozolomide [139]. Temozolo-
mide is an alkylating agent found to have beneﬁcial eﬀects
in the palliative treatment of GB [140]. Whereas glioma cell
lines expressing mutant p53 are sensitized to temozolomide,
the status of p53 does not seem to aﬀect the response
of brain tumor stem cells treated with this drug [141].
Despite the fact that the survival outlook for GB patients
remains poor, recent years have seen progress towards longer
survival, as summarized in an excellent review [4]. Several
targeted therapies are currently in preclinical or clinical
phase I–III trials and examples include small molecule or
antibodyinhibitorsofreceptortyrosinekinases,angiogenesis
regulators, histone deacetylases, heat shock proteins and
mTOR [4, 142]. Early results from monotherapy trials have
been rather disappointing, but a number of emerging drug
candidates used in combination are expected to further
prolong survival of brain tumor patients [4, 142].
What about speciﬁc targeting of brain tumor stem
cells? As mentioned, brain tumor stem cell populations
show resistance to drugs and toxic agents, display eﬃcient
DNA repair, and low tendency to undergo apoptotic cell
death [72]. Screenings to ﬁnd novel small molecules that
speciﬁcally target cancer stem cell populations have been
carried out. Salinomycin is a novel small molecule that
targets breast tumor stem cells and selectively reduces the
proportion of these cells relative to the eﬀect of paclitaxel
[143]. Development of similar drugs to be used in brain
tumortherapyisthereforedesired.Moleculartargetsinbrain
tumor stem cell populations could for instance be diﬀerent
components of the PTEN-PI3K-AKT-WNT signaling net-
works that drive cell growth [144]. Another approach could
be to target brain tumor stem cells with small molecules that
can induce diﬀerentiation, for example, histone deacetylase
inhibitors [145]. Ribosomal DNA transcription (the RNA
pol I machinery) is also an emerging target in cancer therapy
[146]. Depleting cells of ribosomes by blocking production
of ribosomal proteins was shown to induce p53-dependent
inhibition of cell proliferation and morphological diﬀeren-
tiation of glioma cells in vitro [147]. Selective inhibition of
ribosome biogenesis in stem-like cell populations in brain
tumors as another kind of diﬀerentiation therapy should be
explored further.
O n ep r i m ec a n d i d a t ei so fc o u r s ep 5 3i t s e l f .R e s t o r a t i o n
of the p53 tumor suppressor function holds promise in
cancer therapy [148, 149]. Tumors with dysfunctional or no
p53 have been shown to undergo apoptosis or senescence in
vivo upon functional restoration of p53 [150, 151]. When it
comes to the tumor cells, we ﬁrst need to distinguish cells
with no p53 from cells with mutant p53, and cells retaining
wild-type p53. Activation of endogenous wild-type p53 with
small molecules, reactivation of mutant p53, or transfer of
the p53 gene should therefore be considered [152]. Nutlin-3
isacompoundthatdisruptsthebindingbetweenMDM2and
p53leading toactivationandaccumulationoffree p53[153].
Interestingly, activation of endogenous wild type p53 with
Nutlin-3 correlated with restoration of asymmetric breast
cancer stem cell divisions resulting in tumor reduction [74].
This occurred in the absence of any major eﬀectson the bulk
oftumorcells[74].Inanotherstudyitwasfoundthatmutant
p53 reactivation with the drug ellipticine when combined
with5-ﬂuorouracilledtodepletionofcoloncancerstemcells
in vitro [154]. Perhaps the reactivation of p53 speciﬁcally in
brain tumor stem cells could induce permanent diﬀerenti-
ation or apoptosis followed by tumor regression? Apoptosis
is however not frequently seen upon retroviral expression or
activation of endogenous p53 in glioma cell lines [36], but
overexpression of p53 by adenovirus may sensitize glioma
cells toapoptosis [155].Indeed, adenoviral expression ofp53
has been extensively tested in glioma [156].
There are some pitfalls when it comes to p53 reactivation
that need to be discussed. For instance, maintaining wild
type p53 could have a prosurvival eﬀect on tumors that are
notintrinsically pronetoapoptosis[157].Intumorsresistant
to cell death, p53 may favor DNA repair and diﬀerentiation
over apoptosis or senescence [157]. For example, wild-
type-p53-containing glioma cell lines are more resistant to
cytotoxic agents than cell lines with mutant p53 [158].
We must also take into consideration that activation of
p53 may lead to the emergence of treatment resistant
brain tumor cells that express mutant p53 or that have
completely lost p53. Moreover, persistent activation of p53
in nearby residing normal neural stem cells could have
adverse negative sideeﬀects such as stem cell depletion and
premature organ aging [58, 159]. Whereas activation of
p53 traditionally has been viewed as the main avenue, the
potential medical applications of inhibiting p53 should also
be realized. In fact, inhibiting p53 protects normal cells from
radiation-induced cell death and can improve recovery after
ischemia in the central nervous system [160]. Unfortunately,
inhibition of p53 activity in nontumorigenic cells could have
a procarcinogenic eﬀect, although encouraging results from
studies in hematopoietic cells indicate that this might not be
t h ec a s e[ 161].
7.ConcludingRemarks
There are a number of remaining unresolved issues with
regard to the existence and phenotype of brain tumor stem
cells and how similar they are to normal neural stem cells [5,
71]. The hypothesis that a normal neural stem or progenitor
cell can evolve to become a brain tumor stem cell perhaps
through a mutation in p53 is a very reasonable one and
has got substantial experimental support [27, 29, 31, 94].
Several lines of evidence in the literature indicate that loss
of p53 aﬀects the properties of adult neural stem cells by
providing a proliferative advantage [31, 73, 90]. Although
loss of p53 on its own does not give rise to brain tumors in
mice, it allows for rapid tumor development in the presence
of persistent mitogen signaling, oncogene activation and
subsequent mutational events [32]. However, we must also
be aware that there are presumably diﬀerent cellular origins
for gliomas and that they could originate from various
regions of the brain [5].Weare nowfacedwith theintriguing
situation in which p53 suppresses tumor development by
restricting expansion of incipient brain tumor stem cells,Journal of Oncology 7
but p53 also retains its conventional roles in controlling
cell cycle progression and apoptosis following stress. Which
one of these p53 activities is the most important one to
circumventduring gliomagenesis, remains to be determined.
We also do not know exactly through which mechanisms
and pathways p53 controls neural stem cell self-renewal, but
once identiﬁed, such mechanisms are putative novel targets
for therapy. Treatment of brain tumor patients presents a
unique challenge, and the selective targeting of brain tumor
stem cell populations, regardless ofwhether they constitutea
minor or major part of the whole tumors needs to be further
explored, in order to become a clinical reality in the future.
Combinationtherapiestargeting bothbraintumorstem cells
and bulk brain tumor cells could turn out to be the most
eﬀective ones. It is of outermost importance to achieve a
permanent eradication of brain tumor cells including brain
tumor stem cells. However, the elimination of all tumor
cells remains a very diﬃcult task when considering the wide
spectrum oftumorcell phenotypes,diﬀerencesinp53status,
and divergent cellular responses to treatment.
Acknowledgments
T h ea u t h o r sa r eg r a t e f u lt oD r sA n n aH e d r ´ en and P´ adraig
D’Arcy for critical reading of the manuscript. Monica Nist´ er
is supported by the Swedish Cancer Society, the Cancer
Society in Stockholm (King Gustav V Jubilee Fund), the
Swedish Research Council, the Swedish Childhood Cancer
Foundation, and the Karolinska University Hospital FoUU.
Mikael Lindstr¨ om is a recipient of a fellowship award from
theSwedishCancerSociety(Cancerfonden)andissupported




secondary glioblastoma,” American Journal of Pathology,v o l .
170, no. 5, pp. 1445–1453, 2007.
[2] F. B. Furnari, T. Fenton, R. M. Bachoo et al., “Malignant
astrocytic glioma: genetics, biology, and paths to treatment,”
Genesand Development, vol.21,no.21, pp. 2683–2710,2007.
[3] D.N.Louis,H.Ohgaki,O.D.Wiestleretal.,“The2007WHO
classiﬁcationof tumours of the central nervous system,” Acta
Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007.
[ 4 ]E .G .v a nM e i r ,C .G .H a d j i p a n a y i s ,A .D .N o r d e n ,H .K .
S h u ,P .Y .W e n ,a n dJ .J .O l s o n ,“ E x c i t i n gn e wa d v a n c e si n
neuro-oncology: the avenue to a cure for malignant glioma,”
CA Cancer Journal for Clinicians, vol. 60, no. 3, pp. 166–193,
2010.
[5] J. T. Huse and E. C. Holland, “Targeting brain cancer:
advances in the molecular pathology of malignant glioma
and medulloblastoma,” Nature Reviews Cancer, vol. 10, no.
5, pp. 319–331, 2010.
[6] D. N. Louis, “The p53 gene and protein in human brain
tumors,”Journal of NeuropathologyandExperimental Neurol-
ogy, vol. 53, no. 1, pp. 11–21, 1994.
[7] M. Nozaki, M. Tada, H. Kobayashi et al., “Roles of the
functional loss of p53 and other genes in astrocytoma
tumorigenesis and progression,” Neuro-Oncology,v o l .1 ,n o .
2, pp. 124–137, 1999.
[ 8 ]K .H .V o u s d e na n dC .P r i v e s ,“ B l i n d e db yt h el i g h t :t h e
growing complexity of p53,” Cell, vol. 137, no. 3, pp. 413–
431, 2009.
[9] S. A. Llaguno,J.Chen, C. H. Kwon, and L. F. Parada,“Neural
and cancer stem cells in tumor suppressor mouse models
of malignant astrocytoma,” Cold Spring Harbor Symposia on
Quantitative Biology, vol. 73, pp. 421–426, 2008.
[10] T. Zhao and Y. Xu, “p53 and stem cells: new developments
and new concerns,” Trends in Cell Biology,v o l .2 0 ,n o .3 ,p p .
170–175, 2010.
[11] E. Hulleman and K. Helin, “Molecular mechanisms in
gliomagenesis,” Advances in Cancer Research, vol. 94, no. 1,
pp. 1–27, 2005.
[12] R. McLendon,A.Friedman, D. Bigneret al.,“Comprehensive
genomic characterization deﬁnes human glioblastoma genes
and core pathways,” Nature, vol. 455, no. 7216, pp. 1061–
1068, 2008.
[13] D. W. Parsons, S. Jones, X. Zhang et al., “An integrated
genomic analysis of human glioblastoma multiforme,” Sci-
ence, vol. 321, no. 5897, pp. 1807–1812, 2008.
[14] H. S. Phillips, S. Kharbanda, R. Chen et al., “Molecular
subclasses of high-grade glioma predict prognosis, delineate
a pattern of disease progression, and resemble stages in
neurogenesis,” Cancer Cell, vol. 9, no. 3, pp. 157–173, 2006.
[15] A. VonDeimling, R. H.Eibl, H.Ohgakiet al.,“p53 mutations
are associated with 17p allelic loss in grade II and grade III
astrocytoma,” Cancer Research, vol. 52, no. 10, pp. 2987–
2990, 1992.
[16] A. Von Deimling, D. N. Louis, A. G. Menon et al., “Deletions
onthelongarmofchromosome17inpilocyticastrocytoma,”
Acta Neuropathologica, vol. 86, no. 1, pp. 81–85, 1993.
[17] D. P. Lane, “p53, guardian of the genome,” Nature, vol. 358,
no. 6381, pp. 15–16, 1992.
[18] K. H. Vousden and D. P. Lane, “p53 in health and disease,”
Nature Reviews Molecular Cell Biology, vol. 8, no. 4, pp. 275–
283, 2007.
[19] R. Zhao, K. Gish, M. Murphy et al., “Analysis of p53-
regulated gene expression patterns using oligonucleotide
arrays,” Genes and Development, vol. 14, no. 8, pp. 981–993,
2000.
[20] D. W. Meek and C. W. Anderson, “Posttranslational mod-
iﬁcation of p53: cooperative integrators of function,” Cold
Spring Harbor Perspectives in Biology,v o l .1 ,n o .6 ,a r t i c l en o .
a000950, 2009.
[21] T. Soussi and K. G. Wiman, “Shaping genetic alterations in
humancancer: thep53 mutationparadigm,” Cancer Cell,v o l .
12, no. 4, pp. 303–312, 2007.
[22] M. Wade, Y. V. Wang, and G. M. Wahl, “The p53 orchestra:
Mdm2 and Mdmx set the tone,” Trends in Cell Biology,v o l .
20, no. 5, pp. 299–309, 2010.
[23] G. Reifenberger, L. Liu, K. Ichimura, E. E. Schmidt, and V.
P. Collins, “Ampliﬁcation and overexpression of the MDM2
gene in a subset of human malignant gliomas without p53
mutations,” Cancer Research, vol. 53, no. 12, pp. 2736–2739,
1993.
[24] M. J. Riemenschneider, R. Buschges, M. Wolter et al.,
“Ampliﬁcation and overexpression of the MDM4 (MDMX)
gene from 1q32 in a subset of malignant gliomas without
TP53 mutation or MDM2 ampliﬁcation,” Cancer Research,
vol. 59, no. 24, pp. 6091–6096, 1999.
[25] D. Malkin, F. P. Li, L. C. Strong et al., “Germ line p53
mutations in a familial syndrome of breast cancer, sarcomas,8 Journal of Oncology
and other neoplasms,” Science, vol. 250, no. 4985, pp. 1233–
1238, 1990.
[ 2 6 ]A .P .K y r i t s i s ,M .L .B o n d y ,M .X i a oe ta l . ,“ G e r m l i n ep 5 3
gene mutations in subsets of glioma patients,” Journal of the
National Cancer Institute, vol. 86, no. 5, pp. 344–349, 1994.
[27] H.Zheng,H.Ying,H.Yanetal.,“p53andPtencontrolneural
andgliomastem/progenitorcellrenewalanddiﬀerentiation,”
Nature, vol. 455, no. 7216, pp. 1129–1133, 2008.
[ 2 8 ]J .L i ,C .Y e n ,D .L i a we ta l . ,“ P T E N ,ap u t a t i v ep r o t e i n
tyrosine phosphatase gene mutated in human brain, breast,
and prostate cancer,” Science, vol. 275, no. 5308, pp. 1943–
1947, 1997.
[29] S. Alcantara Llaguno, J. Chen, C. H. Kwon et al., “Malignant
astrocytomas originate from neural stem/progenitor cells in
a somatic tumor suppressor mouse model,” Cancer Cell,v o l .
15, no. 1, pp. 45–56, 2009.
[30] A. Del Arco, J. Garcia, C. Arribas et al., “Timing of
p53 mutations during astrocytoma tumorigenesis,” Human
Molecular Genetics,vol. 2, no. 10, pp. 1687–1690, 1993.
[31] S. Gil-Perotin, M. Marin-Husstege, J. Li et al., “Loss of
p53 induces changes in the behavior of subventricular zone
cells: implication for the genesis of Glial tumors,” Journal of
Neuroscience, vol. 26, no. 4, pp. 1107–1116, 2006.
[ 3 2 ]S .M .H e d e ,I .H a n s s o n ,G .B .A ﬁ n ke ta l . ,“ G F A Pp r o m o t e r
driven transgenic expression of PDGFB in the mouse brain
leads to glioblastoma in a Trp53 null background,” Glia,v o l .
57, no. 11, pp. 1143–1153, 2009.
[33] W. B. Jacobs, D. R. Kaplan, and F. D. Miller, “The p53
family in nervous system development and disease,” Journal
of Neurochemistry, vol. 97, no. 6, pp. 1571–1584, 2006.
[34] D. Sidransky, T. Mikkelsen, K. Schwechheimer, M. L. Rosen-
blum, W. Cavanee, and B. Vogelstein, “Clonal expansion of
p53 mutant cells is associated with brain tumour progres-
sion,” Nature, vol. 355, no. 6363, pp. 846–847, 1992.
[35] J. Ikeda, M. Tada, N. Ishii et al., “Restoration of endogenous
wild-type p53 activity in a glioblastoma cell line with
intrinsictemperature-sensitive p53induces growtharrest but
not apoptosis,” International Journal of Cancer, vol. 94, no. 1,
pp. 35–43, 2001.
[ 3 6 ]A .M e r z a k ,S .R a y n a l ,J .P .R o g e r s ,D .L a w r e n c e ,a n dG .J .
Pilkington, “Human wild type p53 inhibits cell proliferation
andelicitsdramaticmorphologicalchangesinhumanglioma
cell lines in vitro,” Journal of the Neurological Sciences,v o l .
127, no. 2, pp. 125–133, 1994.
[37] E. G. VanMeir,T. Kikuchi, M.Tada et al.,“Analysisofthe p53
gene and its expression in human glioblastoma cells,” Cancer
Research, vol. 54, no. 3, pp. 649–652, 1994.
[38] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman,
“Stem cells, cancer, and cancer stem cells,” Nature, vol. 414,
no. 6859, pp. 105–111, 2001.
[39] G. Keller, “Embryonic stem cell diﬀerentiation: emergence of
a new era in biology and medicine,” Genes and Development,
vol. 19, no. 10, pp. 1129–1155, 2005.
[ 4 0 ]R .G a l l i ,A .G r i t t i ,L .B o n f a n t i ,a n dA .L .V e s c o v i ,“ N e u r a l
stem cells: an overview,” Circulation Research, vol. 92, no. 6,
pp. 598–608, 2003.
[41] R.Galli,A.Gritti,andA.L.Vescovi,“Adult neuralstemcells,”
Methods in Molecular Biology, vol. 438, pp. 67–84, 2008.
[42] C. Lois and A. Alvarez-Buylla, “Proliferating subventricular
zonecells in the adultmammalianforebrain can diﬀerentiate
into neurons and Glia,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 90, no. 5, pp.
2074–2077, 1993.
[ 4 3 ]F .D o e t s c h ,I .C a i l l e ,D .A .L i m ,J .M .G a r c i a - V e r d u g o ,a n d
A. Alvarez-Buylla, “Subventricular zone astrocytes are neural
stem cells in the adult mammalianbrain,” Cell, vol. 97, no. 6,
pp. 703–716, 1999.
[44] J. Altman and G. D. Das, “Autoradiographic and histological
evidence of postnatal hippocampal neurogenesis in rats,”
Journal of Comparative Neurology, vol. 124, no. 3, pp. 319–
335, 1965.
[45] B. A. Reynolds and S. Weiss, “Generation of neurons and
astrocytes from isolated cells of the adult mammaliancentral
nervous system,” Science, vol. 255, no. 5052, pp. 1707–1710,
1992.
[ 4 6 ]A .A l v a r e z - B u y l l a ,M .K o h w i ,T .M .N g u y e n ,a n dF .T .
Merkle, “The heterogeneity of adult neural stem cells and
the emerging complexity of their niche,” Cold Spring Harbor
Symposia on Quantitative Biology, vol.73,pp. 357–365,2008.
[47] L. P. Deleyrolle and B. A. Reynolds, “Isolation, expansion,
and diﬀerentiation of adult Mammalian neural stem and
progenitor cells using the neurosphere assay,” Methods in
Molecular Biology, vol. 549, pp. 91–101, 2009.
[48] C.Altaner,“Glioblastomaandstemcells,”Neoplasma,vol.55,
no. 5, pp. 369–374, 2008.
[49] C. A. O’Brien, A. Kreso, and J. E. Dick, “Cancer stem cells in
solid tumors: an overview,” Seminars in Radiation Oncology,
vol. 19, no. 2, pp. 71–77, 2009.
[50] L.L.C.MarottaandK.Polyak,“Cancerstemcells:amodelin
the making,” Current Opinion in Genetics and Development,
vol. 19, no. 1, pp. 44–50, 2009.
[51] L. Vermeulen, M. R. Sprick, K. Kemper, G. Stassi, and J. P.
Medema, “Cancer stem cells—old concepts, new insights,”
Cell Death and Diﬀerentiation, vol. 15, no. 6, pp. 947–958,
2008.
[52] M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J.
Morrison, and M. F. Clarke, “Prospective identiﬁcation of
tumorigenic breast cancer cells,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 100,
no. 7, pp. 3983–3988, 2003.
[53] S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identiﬁcation of
human brain tumour initiating cells,” Nature, vol. 432, no.
7015, pp. 396–401, 2004.
[ 5 4 ]C .L i ,D .G .H e i d t ,P .D a l e r b ae ta l . ,“ I d e n t i ﬁ c a t i o no f
pancreatic cancer stem cells,” Cancer Research,v o l .6 7 ,n o .3 ,
pp. 1030–1037, 2007.
[55] C. A. O’Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A
humancoloncancer cell capable of initiatingtumour growth
in immunodeﬁcient mice,” Nature, vol. 445, no. 7123, pp.
106–110, 2007.
[56] D. Bonnet and J. E. Dick, “Human acute myeloid leukemia
is organized as a hierarchy that originates from a primitive
hematopoietic cell,” Nature Medicine, vol. 3, no. 7, pp. 730–
737, 1997.
[57] S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells
promote radioresistance by preferential activation of the
DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–
760, 2006.
[58] M. Diehn, R. W. Cho, and M. F. Clarke, “Therapeutic
implications of the cancer stem cell hypothesis,” Seminars in
Radiation Oncology, vol. 19, no. 2, pp. 78–86, 2009.
[59] I. Ischenko, H. Seeliger, M. Schaﬀe r ,K .W .J a u c h ,a n dC .J .
Bruns, “Cancer stem cells: how can we target them?” Current
Medicinal Chemistry, vol. 15, no. 30, pp. 3171–3184, 2008.
[60] N. Shafee, C. R. Smith, S. Wei et al., “Cancer stem cells
contribute to cisplatin resistance in Brca1/p53-mediatedJournal of Oncology 9
mouse mammary tumors,” Cancer Research,v o l .6 8 ,n o .9 ,
pp. 3243–3250, 2008.
[61] R. Galli, E. Binda, U. Orfanelli et al., “Isolation and
characterization of tumorigenic, stem-like neural precursors
from human glioblastoma,” Cancer Research, vol. 64, no. 19,
pp. 7011–7021, 2004.
[ 6 2 ]H .D .H e m m a t i ,I .N a k a n o ,J .A .L a z a r e ﬀ et al., “Cancerous
stem cells canarisefrom pediatric braintumors,”Proceedings
of the National Academy of Sciences of the United States of
America, vol. 100, no. 25, pp. 15178–15183, 2003.
[ 6 3 ]T .N .I g n a t o v a ,V .G .K u k e k o v ,E .D .L a y w e l l ,O .N .S u s l o v ,
F .D .V r i o n i s ,a n dD .A .S t e i n d l e r ,“ H u m a nc o r t i c a lG l i a l
tumors contain neural stem-like cells expressing astroGlial
and neuronal markers in vitro,” Glia, vol. 39, no. 3, pp. 193–
206, 2002.
[64] S. K. Singh, I. D. Clarke, M. Terasaki et al., “Identiﬁcation of
a cancer stem cell in human brain tumors,” Cancer Research,
vol. 63, no. 18, pp. 5821–5828, 2003.
[65] X. Yuan, J. Curtin, Y. Xiong et al., “Isolation of cancer stem
cells from adultglioblastomamultiforme,”Oncogene,v ol.23,
no. 58, pp. 9392–9400, 2004.
[66] M. Varghese, H. Olstorn, C. Sandberg et al., “A comparison
between stem cells from the adult human brain and from
brain tumors,” Neurosurgery, vol. 63, no. 6, pp. 1022–1033,
2008.
[67] R. Pallini, L. Ricci-Vitiani, G. L. Banna et al., “Cancer
stem cell analysis and clinical outcome in patients with
glioblastoma multiforme,” Clinical Cancer Research, vol. 14,
no. 24, pp. 8205–8212, 2008.
[68] F. Zeppernick, R. Ahmadi, B. Campos et al., “Stem cell
marker CD133 aﬀects clinical outcome in glioma patients,”
Clinical Cancer Research, vol. 14, no. 1, pp. 123–129, 2008.
[69] R.Chen,M.C.N ishimura,S.M.Bumbacaetal.,“ Ahierar c h y
of self-renewing tumor-initiating cell types in glioblastoma,”
Cancer Cell, vol. 17, no. 4, pp. 362–375, 2010.
[70] E. Quintana, M. Shackleton, M. S. Sabel, D. R. Fullen, T. M.




exam,” Neuron, vol. 58, no. 6, pp. 832–846, 2008.
[72] A. L. Vescovi, R. Galli, and B. A. Reynolds, “Brain tumour
stem cells,” Nature Reviews Cancer, vol.6, no.6, pp. 425–436,
2006.
[73] K. Meletis, V. Wirta, S. M. Hede, M. Nist´ er, J. Lundeberg,
andJ.Fris´ en, “p53 suppresses the self-renewal of adult neural
stem cells,” Development, vol. 133, no. 2, pp. 363–369, 2006.
[ 7 4 ]A .C i c a l e s e ,G .B o n i z z i ,C .E .P a s ie ta l . ,“ T h et u m o r
suppressor p53 regulates polarity of self-renewing divisions
in mammarystem cells,” Cell, vol. 138, no. 6, pp. 1083–1095,
2009.
[75] Y. Liu, S. E. Elf, T. Asai et al., “The p53 tumor suppressor
protein is a critical regulator of hematopoietic stem cell
behavior,” Cell Cycle, vol. 8, no. 19, pp. 3120–3124, 2009.
[76] Y. Liu, S. E. Elf, Y. Miyata et al., “p53 regulates hematopoietic
stem cell quiescence,” Cell Stem Cell, vol. 4, no. 1, pp. 37–48,
2009.
[77] T. Lin, C. Chao, S. Saito et al., “p53 induces diﬀerentiation
of mouse embryonic stem cells by suppressing Nanog
expression,” Nature Cell Biology, vol. 7, no. 2, pp. 165–171,
2005.
[78] S. Aparicio and C. J. Eaves, “p53: a new kingpin in the stem
cell arena,” Cell, vol. 138, no. 6, pp. 1060–1062, 2009.
[79] V. Krizhanovsky and S. W. Lowe, “Stem cells: the promises
and perils ofp53,” Nature, vol.460, no. 7259, pp. 1085–1086,
2009.
[80] A. M. Puzio-Kuter and A. J. Levine, “Stem cell biology meets
p53,”Nature Biotechnology,vol.27,no.10,pp.914–915,2009.
[81] A. Molchadsky, N. Rivlin, R. Brosh, V. Rotter, and R.
Sarig,“P53is balancingdevelopment,diﬀerentiation andde-
diﬀerentiation to assure cancer prevention,” Carcinogenesis,
vol. 31, no. 9, pp. 1501–1508, 2010.
[82] J. F. Armstrong, M. H. Kaufman, D. J. Harrison, and A.
R. Clarke, “High-frequency developmental abnormalities in
p53-deﬁcient mice,” Current Biology, vol. 5, no. 8, pp. 931–
936, 1995.
[83] V. P. Sah, L. D. Attardi, G. J. Mulligan, B. O. Williams, R. T.
Bronson, and T. Jacks, “A subset of p53-deﬁcient embryos
exhibit exencephaly,” Nature Genetics,vol. 10, no. 2, pp. 175–
180, 1995.
[84] A. Tedeschi and S. Di Giovanni, “The non-apoptotic role of
p53 in neuronal biology: enlightening the dark side of the
moon,” EMBO Reports, vol. 10, no. 6, pp. 576–583, 2009.
[85] S. Medrano, M. Burns-Cusato, M. B. Atienza, D. Rahimi,
and H. Scrable, “Regenerative capacity of neural precursors
in the adult mammalian brain is under the control of p53,”
Neurobiology of Aging, vol. 30, no. 3, pp. 483–497, 2009.
[86] S. Medrano and H. Scrable, “Maintaining appearances—
t h er o l eo fp 5 3i na d u l tn e u r o g e n e s i s , ”Biochemical and
Biophysical Research Communications, vol. 331, no. 3, pp.
828–833, 2005.
[87] N. Billon,A. Terrinoni, C. Jolicoeur et al., “Roles for p53 and
p73duringoligodendrocyte development,”Development,v ol.
131, no. 6, pp. 1211–1220, 2004.
[88] K. Wosik, J. Antel, T. Kuhlmann, W. Br¨ uck, B. Massie, and J.
Nalbantoglu, “Oligodendrocyte injury in multiple sclerosis:
a role for p53,” Journal of Neurochemistry, vol. 85, no. 3, pp.
635–644, 2003.
[89] T. Tsukada, Y. Tomooka, S. Takai et al., “Enhanced prolifer-
ative potential in culture of cells from p53-deﬁcient mice,”
Oncogene, vol. 8, no. 12, pp. 3313–3322, 1993.
[90] A. Armesilla-Diaz, P. Bragado, I. del Valle et al., “p53
regulates the self-renewal and diﬀerentiation of neural
precursors,” Neuroscience, vol. 158, no. 4, pp. 1378–1389,
2009.
[ 9 1 ]M .H a r v e y ,M .J .M c A r t h u r ,C .A .M o n t g o m e r y ,J .S .
Butel, A. Bradley, and L. A. Donehower, “Spontaneous and
carcinogen-induced tumorigenesis in p53-deﬁcient mice,”
Nature Genetics,vol. 5, no. 3, pp. 225–229, 1993.
[92] A. Armesilla-Diaz, G. Elvira, and A. Silva, “p53 regulates the
proliferation, diﬀerentiation and spontaneous transforma-
tion of mesenchymal stem cells,” Experimental Cell Research,
vol. 315, no. 20, pp. 3598–3610, 2009.
[93] S. Godar, T. A. Ince, G. W. Bell et al.,“Growth-inhibitory and
tumor-suppressive functions of p53 depend on its repression
of CD44 expression,” Cell, vol. 134, no. 1, pp. 62–73, 2008.
[ 9 4 ]Y .W a n g ,J .Y a n g ,H .Z h e n ge ta l . ,“ E x p r e s s i o no fm u t a n t
p53 proteins implicates a lineage relationshipbetween neural
stem cells and malignant astrocytic glioma in a murine
model,” Cancer Cell, vol. 15, no. 6, pp. 514–526, 2009.
[ 9 5 ]T .S .J a c q u e s ,A .S w a l e s ,M .J .B r z o z o w s k ie ta l . ,“ C o m -
binations of genetic mutations in the adult neural stem
cell compartment determine brain tumour phenotypes,” The
EMBO Journal, vol. 29, no. 1, pp. 222–235, 2010.
[96] C. H. Kwon, D. Zhao, J. Chen et al., “Pten haploinsuﬃciency
accelerates formation of high-grade astrocytomas,” Cancer
Research, vol. 68, no. 9, pp. 3286–3294, 2008.10 Journal of Oncology
[97] M. L. Burness and D. A. Sipkins, “The stem cell niche in
health and malignancy,” Seminars in Cancer Biology,v o l .2 0 ,
no. 2, pp. 107–115, 2010.
[98] Z. P. Ren, T. Olofsson,M. Qu et al., “Molecular genetic anal-
ysis of p53 intratumoral heterogeneity in human astrocytic
brain tumors,” Journal of Neuropathology and Experimental
Neurology, vol. 66, no. 10, pp. 944–954, 2007.
[ 9 9 ]M .M .I n d a ,R .B o n a v i a ,A .M u k a s ae ta l . ,“ T u m o rh e t -
erogeneity is an active process maintained by a mutant
EGFR-induced cytokine circuit in glioblastoma,” Genes and
Development, vol. 24, no. 16, pp. 1731–1745, 2010.
[100] K. Takahashi and S. Yamanaka, “Induction of pluripotent
stem cells from mouse embryonic and adult ﬁbroblast
cultures by deﬁned factors,”Cell, vol.126,no.4,pp. 663–676,
2006.
[101] H. Hong, K. Takahashi, T. Ichisaka et al., “Suppression of
induced pluripotent stem cell generation by the p53-p21
pathway,” Nature, vol. 460, no. 7259, pp. 1132–1135, 2009.
[102] T. Kawamura, J. Suzuki, Y. V. Wang et al., “Linking the p53
tumoursuppressorpathwayto somaticcell reprogramming,”
Nature, vol. 460, no. 7259, pp. 1140–1144, 2009.
[103] R. M. Marion, K. Strati, H. Li et al., “A p53-mediated DNA
damage response limits reprogramming to ensure iPS cell
genomicintegrity,”Nature,vol.460,no.7259,pp.1149–1153,
2009.
[104] J. Utikal, J. M. Polo, M. Stadtfeld et al., “Immortalization
eliminates a roadblock during cellular reprogramming into
iPS cells,” Nature, vol. 460, no. 7259, pp. 1145–1148, 2009.
[105] H. Li, M. Collado, A. Villasante et al., “The Ink4/Arf locus is
a barrier for iPS cell reprogramming,” Nature, vol. 460, no.
7259, pp. 1136–1139, 2009.
[106] R. M. R. Gangemi, F. Griﬀero, D. Marubbi et al., “SOX2
silencinginglioblastomatumor-initiatingcells causesstopof
proliferation and loss of tumorigenicity,” Stem Cells, vol. 27,
no. 1, pp. 40–48, 2009.
[107] Z. Du, D. Jia, S. Liu et al., “Oct4 in expressed in human
gliomas and promotes colony formation in glioma cells,”
Glia, vol. 57, no. 7, pp. 724–733, 2009.
[108] I. Ben-Porath, M. W. Thomson, V. J. Carey et al., “An
embryonic stem cell-like gene expression signature in poorly
diﬀerentiated aggressive human tumors,” Nature Genetics,
vol. 40, no. 5, pp. 499–507, 2008.
[109] D. S. Kong, M. H. Kim, W. Y. Park et al., “The progression
of gliomas is associated with cancer stem cell phenotype,”
Oncology Reports, vol. 19, no. 3, pp. 639–643, 2008.
[110] J. Wang, H. Wang, Z. Li et al., “c-Myc is required for
maintenance of glioma cancer stem cells,” PLoS ONE,v o l .3 ,
no. 11, article no. e3769, 2008.
[111] M. Nagao, K. Campbell, K. Burns, C. Y. Kuan, A. Trumpp,
and M. Nakafuku, “Coordinated control of self-renewal and
diﬀerentiation of neural stem cells by Myc and the p19-p53
pathway,” J o u r n a lo fC e l lB i o l o g y , vol. 183, no. 7, pp. 1243–
1257, 2008.
[112] M. I. Aladjem, B. T. Spike, L. W. Rodewald et al., “ES cells
do not activate p53-dependent stress responses and undergo
p53-independent apoptosis in response to DNA damage,”
Current Biology, vol. 8, no. 3, pp. 145–155, 1998.
[113] K. L. Ligon, E. Huillard, S. Mehta et al., “Olig2-regulated
lineage-restricted pathway controls replication competence
in neural stem cells and malignant glioma,” Neuron, vol. 53,
no. 4, pp. 503–517, 2007.
[114] T. E. Kippin, D. J. Martens, and D. Van Der Kooy, “p21
loss compromises the relative quiescence of forebrain stem
cell proliferation leading to exhaustion of their proliferation
capacity,” GenesandDevelopment,vol.19,no.6,pp.756–767,
2005.
[115] B. Stecca and A. Ruiz i Altaba, “A GLI1-p53 inhibitory loop
controls neural stem cell and tumour cell numbers,” EMBO
Journal, vol. 28, no. 6, pp. 663–676, 2009.
[116] M. Zbinden, A. Duquet, A. Lorente-Trigos, S. N. Ngwabyt,
I. Borges, and A. Ruiz i Altaba, “NANOG regulates glioma
stem cells and is essential in vivo acting in a cross-functional
network with GLI1 and p53,” EMBO Journal, vol. 29, pp.
2659–2674, 2010.
[117] S. Brandner, “Nanog, Gli, and p53: a new network of
stemnessindevelopmentandcancer,”EMBOJournal,vol.29,
no. 15, pp. 2475–2476, 2010.
[118] A. H. Stegh, C. Brennan, J. A. Mahoney et al., “Glioma
oncoprotein Bc12L12 inhibits the p53 tumor suppressor,”
Genesand Development,vol.24,no. 19,pp. 2194–2204,2010.
[119] M. Groszer, R. Erickson, D. D. Scripture-Adams et al.,
“PTEN negatively regulates neural stem cell self-renewal by
modulating G-G cell cycle entry,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 103,
no. 1, pp. 111–116, 2006.
[120] M. Groszer, R. Erickson, D. D. Scripture-Adams et al., “Neg-
ative regulation of neural stem/progenitor cell proliferation
by the Pten tumor suppressor gene in vivo,” Science,vol. 294,
no. 5549, pp. 2186–2189, 2001.
[121] H. Zheng, H. Ying, H. Yan et al., “Pten and p53 converge on
c-Myc to control diﬀerentiation, self-renewal, and transfor-
mation of normaland neoplastic stem cells in glioblastoma,”
ColdSpringHarbor Symposia onQuantitative Biology,v ol.73,
pp. 427–437, 2008.
[122] H. Hermeking, “p53 enters the microRNA world,” Cancer
Cell, vol. 12, no. 5, pp. 414–418, 2007.
[123] Y. Zhu,F. Guignard, D. Zhao et al.,“Early inactivation of p53
tumor suppressor gene cooperating with NF1 loss induces
malignant astrocytoma,” Cancer Cell, vol. 8, no. 2, pp. 119–
130, 2005.
[124] N. Lindberg, M. Kastemar, T. Olofsson, A. Smits, and L.
Uhrbom, “Oligodendrocyte progenitor cells can act as cell of
origin for experimental glioma,” Oncogene, vol. 28, no. 23,
pp. 2266–2275, 2009.
[125] C.Dai,J.C.Celestino,Y.Okada,D.N.Louis,G.N.Fuller,and
E. C. Holland, “PDGF autocrine stimulation dediﬀerentiates
cultured astrocytes and induces oligodendrogliomas from
and oligoastrocytomas neural progenitors and astrocytes in
vivo,”Genesand Development,vol.15,no.15,pp. 1913–1925,
2001.
[126] I. Appolloni, F. Calzolari, E. Tutucci et al., “PDGF-B induces
ahomogeneousclassofoligodendrogliomasfromembryonic
neural progenitors,” International Journal of Cancer, vol. 124,
no. 10, pp. 2251–2259, 2009.
[127] F. Calzolari and P. Malatesta, “Recent insights into PDGF-
induced gliomagenesis,” Brain Pathology,v o l .2 0 ,n o .3 ,p p .
527–538, 2010.
[128] L. Uhrbom, G. Hesselager, M. Nist´ er, and B. Westermark,
“Induction of brain tumors in mice using a recombinant
platelet-derived growth factor B-chain retrovirus,” Cancer
Research, vol. 58, no. 23, pp. 5275–5279, 1998.
[129] D. Hambardzumyan, N. M. Amankulor, K. Y. Helmy, O. J.
Becher, and E. C. Holland, “Modeling adult gliomas using
RCAS/t-va technology,” Translational Oncology,v o l .2 ,n o .2 ,
pp. 89–95, 2009.
[130] L.UhrbomandE.C.Holland,“Modelinggliomagenesiswith
somatic cell gene transfer using retroviral vectors,” Journal of
Neuro-Oncology, vol. 53, no. 3, pp. 297–305, 2001.Journal of Oncology 11
[131] J. Andrae, R. Gallini, and C. Betsholtz, “Role of platelet-
derived growth factors in physiology and medicine,” Genes
and Development, vol. 22, no. 10, pp. 1276–1312, 2008.
[132] M. Hermanson, K. Funa, J. Koopmann et al., “Association of
lossofheterozygosityonchromosome17pwithhighplatelet-
derived growth factor α receptor expression in human
malignant gliomas,” Cancer Research, vol. 56, no. 1, pp. 164–
171, 1996.
[133] R. G. W. Verhaak, K. A. Hoadley, E. Purdom et al.,
“Integrated genomic analysis identiﬁes clinically relevant
subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR, and NF1,” Cancer Cell, vol. 17, no.
1, pp. 98–110, 2010.
[134] G. Hesselager, L. Uhrbom, B. Westermark, and M. Nist´ er,
“Complementary eﬀects of platelet-derived growth factor
autocrine stimulation and p53 or INK4a-Arf deletion in a
mouse glioma model,” Cancer Research, vol. 63, no. 15, pp.
4305–4309, 2003.
[135] A. R. Calver, A. C. Hall, W. P. Yu et al., “Oligodendrocyte
population dynamics and the role of PDGF in vivo,” Neuron,
vol. 20, no. 5, pp. 869–882, 1998.
[136] J. Andrae, G. Aﬁnk, X. Q. Zhang, W. Wurst, and M. Nist´ er,
“Forced expression of platelet-derived growth factor B in the
mouse cerebellar primordium changes cell migration during
midline fusion and causes cerebellar ectopia,” Molecular and
Cellular Neuroscience, vol. 26, no. 2, pp. 308–321, 2004.
[137] A. Claes, A. J. Idema, and P. Wesseling, “Diﬀuse glioma
growth: a guerilla war,” Acta Neuropathologica, vol. 114, no.
5, pp. 443–458, 2007.
[138] L.Cheng,S.Bao,andJ.N.Rich,“Potentialtherapeutic impli-
cations of cancer stem cells in glioblastoma,” Biochemical
Pharmacology, vol. 80, no. 5, pp. 654–665, 2010.
[139] P. Y. Wen and S. Kesari, “Malignant gliomas in adults,” New
England Journal of Medicine, vol. 359, no. 5, pp. 492–507,
2008.
[140] W. K. A. Yung, “Temozolomide in malignant gliomas,”
Seminars in Oncology, vol. 27, no. 3, pp. 27–34, 2000.
[141] M. D. Blough, D. C. Beauchamp, M. R. Westgate, J. J.
Kelly, and J. G. Cairncross, “Eﬀect of aberrant p53 function
on temozolomide sensitivity of glioma cell lines and brain
tumor initiating cells from glioblastoma,” Journal of Neuro-
Oncology. In press.
[142] J. N. Rich and D. D. Bigner, “Development of novel targeted
therapies in the treatment of malignant glioma,” Nature
Reviews Drug Discovery, vol. 3, no. 5, pp. 430–446, 2004.
[143] P. B. Gupta, T. T. Onder, G. Jiang et al., “Identiﬁcation of
selective inhibitors of cancer stem cells by high-throughput
screening,” Cell, vol. 138, no. 4, pp. 645–659, 2009.
[144] J. Dietrich, E. L. Diamond, and S. Kesari, “Glioma stem cell
signaling: therapeutic opportunities and challenges,” Expert
Review of Anticancer Therapy, vol. 10, no. 5, pp. 709–722,
2010.
[145] B. Campos, F. Wan, M. Farhadi et al., “Diﬀerentiation
therapy exerts antitumor eﬀects on stem-like glioma cells,”
ClinicalCancerResearch,vol.16,no.10,pp.2715–2728,2010.
[146] D. Drygin, W. G. Rice, and I. Grummt, “The RNA poly-
merase i transcription machinery: an emerging target for the
treatment of cancer,” Annual Review of Pharmacology and
Toxicology, vol. 50, pp. 131–156, 2010.
[147] M. S. Lindstr¨ om and M. Nist´ er, “Silencing of ribosomal
protein S9 elicits a multitude of cellular responses inhibiting
thegrowthofcancercellssubsequenttop53activation,”PLoS
ONE, vol. 5, no. 3, article no. e9578, 2010.
[148] V. J. N. Bykov, G. Selivanova, and K. G. Wiman, “Small
molecules that reactivate mutant p53,” European Journal of
Cancer, vol. 39, no. 13, pp. 1828–1834, 2003.
[149] G. Selivanova and K. G. Wiman, “Reactivation of mutant
p53: molecular mechanisms and therapeutic potential,”
Oncogene, vol. 26, no. 15, pp. 2243–2254, 2007.
[150] A. Ventura, D. G. Kirsch, M. E. McLaughlin et al., “Restora-
tion of p53 function leads to tumour regression in vivo,”
Nature, vol. 445, no. 7128, pp. 661–665, 2007.
[151] W. Xue, L. Zender, C. Miething et al., “Senescence and
tumour clearance is triggered by p53 restoration in murine
liver carcinomas,” Nature, vol. 445, no. 7128, pp. 656–660,
2007.
[152] D. P. Lane, C. F. Cheok, and S. Lain, “p53-based cancer
therapy,” Cold Spring Harbor Perspectives in Biology,v o l .2 ,
article no. a001222, 2010.
[153] L. T. Vassilev, “MDM2 inhibitors for cancer therapy,” Trends
in Molecular Medicine, vol. 13, no. 1, pp. 23–31, 2007.
[154] C. Huang, X. M. Zhang, R. T. Tavaluc et al., “The com-
bination of 5-ﬂuorouracil plus p53 pathway restoration is
associated with depletion of p53-deﬁcient or mutant p53-
expressing putative colon cancer stem cells,” Cancer Biology
and Therapy, vol. 8, no. 22, pp. 2186–2193, 2009.
[155] H. Li, H. Lochmuller, V. W. Yong, G. Karpati, and J. Nal-
bantoglu, “Adenovirus-mediated wild-type p53gene transfer
and overexpression induces apoptosis of human glioma
cells independent of endogenous p53 status,” Journal of
Neuropathology and Experimental Neurology, vol. 56, no. 8,
pp. 872–878, 1997.
[156] F. F. Lang, J. M. Bruner, G. N. Fuller et al., “Phase I trial of
adenovirus-mediated p53 gene therapy for recurrent glioma:
biological and clinical results,” Journal of Clinical Oncology,
vol. 21, no. 13, pp. 2508–2518, 2003.
[157] A. V. Gudkov and E. A. Komarova, “Pathologies associated
with the p53 response,” Cold Spring Harbor Perspectives in
Biology, vol. 2, no. 7, article no. a001180, 2010.
[158] L. F. Z. Batista, W. P. Roos, M. Christmann, C. F. M. Menck,
and B. Kaina, “Diﬀerential sensitivity of malignant glioma
cells to methylating and chloroethylating anticancer drugs:
P53 determines the switch by regulating xpc, ddb2,and DNA
double-strand breaks,” Cancer Research, vol. 67, no. 24, pp.
11886–11895, 2007.
[159] N. E. Sharpless and R. A. DePinho, “How stem cells age and
why this makes us grow old,” Nature Reviews Molecular Cell
Biology, vol. 8, no. 9, pp. 703–713, 2007.
[160] YU. Luo, C. C. Kuo, H. Shen et al., “Delayed treatment with
a p53 inhibitor enhances recovery in stroke brain,” Annals of
Neurology, vol. 65, no. 5, pp. 520–530, 2009.
[161] K. I. Leonova, J. Shneyder, M. P. Antoch et al., “A
small molecule inhibitor of p53 stimulates ampliﬁcation
of hematopoietic stem cells but does not promote tumor
developmentinmice,” Cell Cycle,vol.9,no.7,pp.1434–1443,
2010.